Headache associated with travoprost
Medical hypothesis, discovery & innovation in optometry,
Vol. 4 No. 3 (2023),
3 October 2023
,
Page 135-140
https://doi.org/10.51329/mehdioptometry183
Abstract
Background: Putative adverse effects of prostaglandin analogs in patients treated for glaucoma include periocular skin darkening, herpes simplex keratitis, cystoid macular edema, iritis, and headaches. Here, we report a case of migraine headache after a travoprost administration and discuss the role of prostaglandin analogs in migraine-like headaches.Case Presentation: A 70-year-old man visited the hospital complaining of pain, redness, and sensitivity to light for 1 week associated with gradual loss of vision in the right eye after cataract surgery, which had been performed 2 years prior. After the examination, the patient was diagnosed with pseudophakic bullous keratopathy and advised to undergo optical penetrating keratoplasty of the right eye. On postoperative day 3, his intraocular pressure (IOP) was 30 mmHg at 10:00 AM in the right eye. A single dose of 0.004% travoprost was instilled in the right eye on the same day. His IOP decreased to 16 mmHg at 2:00 PM. The next day, he presented with migraine-like headache that had started within 1 h after the instillation the previous night. Unremarkable neurological examination and neuroimaging suggested that travoprost had caused the migraine. Although the headache gradually resolved, it reappeared after the administration of other prostaglandins. Trabeculectomy was performed on the right side. The IOP was controlled, and the headache was resolved.
Conclusions: This case indicates a potential causal relationship between topical prostaglandin analogs and migraine-like headaches, as evidenced by symptom resolution upon discontinuation. However, large-scale studies including control groups are required to prove a causal relationship between topical prostaglandin analog administrations and headache development.
Keywords:
- migraine
- headaches
- prostaglandin analogues
- travatan Z
- xalatan
- intraocular pressures
References
1. Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29(4):382-9. doi: 10.1089/jop.2012.0186 pmid: 23231442
2. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277-e284. doi: 10.1111/aos.13568 pmid: 29144028
3. Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30(2-3):102-9. doi: 10.1089/jop.2013.0179 pmid: 24359106
4. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008;53 Suppl1:S69-84. doi: 10.1016/j.survophthal.2008.08.012 pmid: 19038626
5. Barot M, Bagui M, Gokulgandhi MR, Mitra AK. Prodrug strategies in ocular drug delivery. Med Chem. 2012;8(4):753-68. doi: 10.2174/157340612801216283 pmid: 22530907
6. Reddy S, Sahay P, Padhy D, Sarangi S, Suar M, Modak R, et al. Tear biomarkers in latanoprost and bimatoprost treated eyes. PLoS One. 2018;13(8):e0201740. doi: 10.1371/journal.pone.0201740 pmid: 30080906
7. Kalikivayi V, Joseph J, Mathews BT, Maheswari R, Vadakara SM, Jacob SC. Reversal of retinal pigment epithelial detachment after cessation of topical travoprost therapy. Int Ophthalmol. 2018;38(5):2227-2231. doi: 10.1007/s10792-017-0711-3 pmid: 29569087
8. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53(2):176-179. doi: 10.1007/s10384-008-0623-x pmid: 19333704
9. Arbabi A, Bao X, Shalaby WS, Razeghinejad R. Systemic side effects of glaucoma medications. Clin Exp Optom. 2022;105(2):157-165. doi: 10.1080/08164622.2021.1964331 pmid: 34402741
10. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47 Suppl 1:S6-12. doi: 10.1016/s0039-6257(02)00302-8 pmid: 12204697
11. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol. 2001;119(2):300-1. pmid: 11176999
12. Konstas AG, Mikropoulos D, Haidich AB, Ntampos KS, Stewart WC. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol. 2009;93(4):481-5. doi: 10.1136/bjo.2008.147322 pmid: 19019932
13. Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010;4:741-64. doi: 10.2147/opth.s10441 pmid: 20689791
14. Yesilirmak N, Alt?nors DD. A silicone hydrogel contact lens after 7 years of continuous wear. Cont Lens Anterior Eye. 2013;36(4):204-6. doi: 10.1016/j.clae.2013.03.001 pmid: 23587839
15. Siu GD, Young AL, Jhanji V. Alternatives to corneal transplantation for the management of bullous keratopathy. Curr Opin Ophthalmol. 2014;25(4):347-52. doi: 10.1097/ICU.0000000000000062 pmid: 24807064
16. Tan DT, Janardhanan P, Zhou H, Chan YH, Htoon HM, Ang LP, et al. Penetrating keratoplasty in Asian eyes: the Singapore Corneal Transplant Study. Ophthalmology. 2008;115(6):975-982.e1. doi: 10.1016/j.ophtha.2007.08.049 pmid: 18061267
17. Liu Y, Li X, Li W, Jiu X, Tian M. Systematic review and meta-analysis of femtosecond laser-enabled keratoplasty versus conventional penetrating keratoplasty. Eur J Ophthalmol. 2021;31(3):976-987. doi: 10.1177/1120672120914488 pmid: 32223431
18. Nocentini A, Supuran CT. Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019). Expert Opin Ther Pat. 2019;29(10):805-815. doi: 10.1080/13543776.2019.1665023 pmid: 31486689
19. Boey PY, Mehta JS, Ho CL, Tan DT, Wong TT. Outcomes of trabeculectomy after descemet stripping automated endothelial keratoplasty: a comparison with penetrating keratoplasty. Am J Ophthalmol. 2012;153(6):1091-8.e2. doi: 10.1016/j.ajo.2011.12.014 pmid: 22397954
20. Dwivedi R, Somerville T, Cheeseman R, Rogers C, Batterbury M, Choudhary A. Deep sclerectomy and trabeculectomy augmented with Mitomycin C: 2-year post-operative outcomes. Graefes Arch Clin Exp Ophthalmol. 2021;259(7):1965-1974. doi: 10.1007/s00417-021-05144-w pmid: 33683432
21. Tfelt-Hansen P, Block G, Dahlöf C, Diener HC, Ferrari MD, Goadsby PJ, et al; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20(9):765-86. doi: 10.1046/j.1468-2982.2000.00117.x pmid: 11167908
22. Pietrobon D, Moskowitz MA. Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nat Rev Neurosci. 2014;15(6):379-93. doi: 10.1038/nrn3770 pmid: 24857965
23. Novack GD, O’Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc. 2002;50(5):956-62. doi: 10.1046/j.1532-5415.2002.50226.x pmid: 12028187
24. Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandins in migraine: update. Curr Opin Neurol. 2013;26(3):269-75. doi: 10.1097/WCO.0b013e328360864b pmid: 23519238
25. Schnober D, Hubatsch DA, Scherzer ML. Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy. Clin Ophthalmol. 2015;9:825-32. doi: 10.2147/OPTH.S80880 pmid: 26005326
26. Ashina M, Hansen JM, Á Dunga BO, Olesen J. Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol. 2017;13(12):713-724. doi: 10.1038/nrneurol.2017.137 pmid: 28984313
27. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47 Suppl 1:S219. doi: 10.1016/s0039-6257(02)00328-4 pmid: 12204718
28. Wang H, Masselos K, Kalloniatis M, Phu J. Headaches related to latanoprost in open-angle glaucoma. Clin Exp Optom. 2021;104(5):625-633. doi: 10.1080/08164622.2021.1878846 pmid: 33689660
29. Li J, Wang X, Xu G, Deng R, Wu L, Zhang L, Chen Z. Comparison of the effectiveness and safety of travoprost and latanoprost for the management of open-angle glaucoma given as an evening dose. Exp Ther Med. 2020;20(5):24. doi: 10.3892/etm.2020.9152 pmid: 32934689
30. Shin J, Lee JW, Choi BS, Yun EY, Jung JH, Kim EA, et al. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma. J Ocul Pharmacol Ther. 2014;30(10):803-9. doi: 10.1089/jop.2014.0034 pmid: 25285367
31. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688-703. doi: 10.1016/s0002-9394(03)00098-9 pmid: 12719078
32. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM; Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18(3):110-21. doi: 10.1007/BF02850299 pmid: 11571823
33. Zimmerman TJ, Stewart WC; Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther. 2003;19(5):405-15. doi: 10.1089/108076803322472971 pmid: 14583133
34. Fan S, Agrawal A, Gulati V, Neely DG, Toris CB. Daytime and nighttime effects of brimonidine on IOP and aqueous humor dynamics in participants with ocular hypertension. J Glaucoma. 2014;23(5):276-81. doi: 10.1097/IJG.0000000000000051 pmid: 24886701
35. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4):337-46. doi: 10.2147/tcrm.2006.2.4.337 pmid: 18360646
2. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277-e284. doi: 10.1111/aos.13568 pmid: 29144028
3. Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30(2-3):102-9. doi: 10.1089/jop.2013.0179 pmid: 24359106
4. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008;53 Suppl1:S69-84. doi: 10.1016/j.survophthal.2008.08.012 pmid: 19038626
5. Barot M, Bagui M, Gokulgandhi MR, Mitra AK. Prodrug strategies in ocular drug delivery. Med Chem. 2012;8(4):753-68. doi: 10.2174/157340612801216283 pmid: 22530907
6. Reddy S, Sahay P, Padhy D, Sarangi S, Suar M, Modak R, et al. Tear biomarkers in latanoprost and bimatoprost treated eyes. PLoS One. 2018;13(8):e0201740. doi: 10.1371/journal.pone.0201740 pmid: 30080906
7. Kalikivayi V, Joseph J, Mathews BT, Maheswari R, Vadakara SM, Jacob SC. Reversal of retinal pigment epithelial detachment after cessation of topical travoprost therapy. Int Ophthalmol. 2018;38(5):2227-2231. doi: 10.1007/s10792-017-0711-3 pmid: 29569087
8. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53(2):176-179. doi: 10.1007/s10384-008-0623-x pmid: 19333704
9. Arbabi A, Bao X, Shalaby WS, Razeghinejad R. Systemic side effects of glaucoma medications. Clin Exp Optom. 2022;105(2):157-165. doi: 10.1080/08164622.2021.1964331 pmid: 34402741
10. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47 Suppl 1:S6-12. doi: 10.1016/s0039-6257(02)00302-8 pmid: 12204697
11. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol. 2001;119(2):300-1. pmid: 11176999
12. Konstas AG, Mikropoulos D, Haidich AB, Ntampos KS, Stewart WC. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol. 2009;93(4):481-5. doi: 10.1136/bjo.2008.147322 pmid: 19019932
13. Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010;4:741-64. doi: 10.2147/opth.s10441 pmid: 20689791
14. Yesilirmak N, Alt?nors DD. A silicone hydrogel contact lens after 7 years of continuous wear. Cont Lens Anterior Eye. 2013;36(4):204-6. doi: 10.1016/j.clae.2013.03.001 pmid: 23587839
15. Siu GD, Young AL, Jhanji V. Alternatives to corneal transplantation for the management of bullous keratopathy. Curr Opin Ophthalmol. 2014;25(4):347-52. doi: 10.1097/ICU.0000000000000062 pmid: 24807064
16. Tan DT, Janardhanan P, Zhou H, Chan YH, Htoon HM, Ang LP, et al. Penetrating keratoplasty in Asian eyes: the Singapore Corneal Transplant Study. Ophthalmology. 2008;115(6):975-982.e1. doi: 10.1016/j.ophtha.2007.08.049 pmid: 18061267
17. Liu Y, Li X, Li W, Jiu X, Tian M. Systematic review and meta-analysis of femtosecond laser-enabled keratoplasty versus conventional penetrating keratoplasty. Eur J Ophthalmol. 2021;31(3):976-987. doi: 10.1177/1120672120914488 pmid: 32223431
18. Nocentini A, Supuran CT. Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019). Expert Opin Ther Pat. 2019;29(10):805-815. doi: 10.1080/13543776.2019.1665023 pmid: 31486689
19. Boey PY, Mehta JS, Ho CL, Tan DT, Wong TT. Outcomes of trabeculectomy after descemet stripping automated endothelial keratoplasty: a comparison with penetrating keratoplasty. Am J Ophthalmol. 2012;153(6):1091-8.e2. doi: 10.1016/j.ajo.2011.12.014 pmid: 22397954
20. Dwivedi R, Somerville T, Cheeseman R, Rogers C, Batterbury M, Choudhary A. Deep sclerectomy and trabeculectomy augmented with Mitomycin C: 2-year post-operative outcomes. Graefes Arch Clin Exp Ophthalmol. 2021;259(7):1965-1974. doi: 10.1007/s00417-021-05144-w pmid: 33683432
21. Tfelt-Hansen P, Block G, Dahlöf C, Diener HC, Ferrari MD, Goadsby PJ, et al; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20(9):765-86. doi: 10.1046/j.1468-2982.2000.00117.x pmid: 11167908
22. Pietrobon D, Moskowitz MA. Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nat Rev Neurosci. 2014;15(6):379-93. doi: 10.1038/nrn3770 pmid: 24857965
23. Novack GD, O’Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc. 2002;50(5):956-62. doi: 10.1046/j.1532-5415.2002.50226.x pmid: 12028187
24. Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandins in migraine: update. Curr Opin Neurol. 2013;26(3):269-75. doi: 10.1097/WCO.0b013e328360864b pmid: 23519238
25. Schnober D, Hubatsch DA, Scherzer ML. Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy. Clin Ophthalmol. 2015;9:825-32. doi: 10.2147/OPTH.S80880 pmid: 26005326
26. Ashina M, Hansen JM, Á Dunga BO, Olesen J. Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol. 2017;13(12):713-724. doi: 10.1038/nrneurol.2017.137 pmid: 28984313
27. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47 Suppl 1:S219. doi: 10.1016/s0039-6257(02)00328-4 pmid: 12204718
28. Wang H, Masselos K, Kalloniatis M, Phu J. Headaches related to latanoprost in open-angle glaucoma. Clin Exp Optom. 2021;104(5):625-633. doi: 10.1080/08164622.2021.1878846 pmid: 33689660
29. Li J, Wang X, Xu G, Deng R, Wu L, Zhang L, Chen Z. Comparison of the effectiveness and safety of travoprost and latanoprost for the management of open-angle glaucoma given as an evening dose. Exp Ther Med. 2020;20(5):24. doi: 10.3892/etm.2020.9152 pmid: 32934689
30. Shin J, Lee JW, Choi BS, Yun EY, Jung JH, Kim EA, et al. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma. J Ocul Pharmacol Ther. 2014;30(10):803-9. doi: 10.1089/jop.2014.0034 pmid: 25285367
31. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688-703. doi: 10.1016/s0002-9394(03)00098-9 pmid: 12719078
32. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM; Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18(3):110-21. doi: 10.1007/BF02850299 pmid: 11571823
33. Zimmerman TJ, Stewart WC; Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther. 2003;19(5):405-15. doi: 10.1089/108076803322472971 pmid: 14583133
34. Fan S, Agrawal A, Gulati V, Neely DG, Toris CB. Daytime and nighttime effects of brimonidine on IOP and aqueous humor dynamics in participants with ocular hypertension. J Glaucoma. 2014;23(5):276-81. doi: 10.1097/IJG.0000000000000051 pmid: 24886701
35. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4):337-46. doi: 10.2147/tcrm.2006.2.4.337 pmid: 18360646
- Abstract Viewed: 0 times
- Full Text PDF Downloaded: 0 times